SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and high short interest as investors weigh its aggressive growth narrative against broader market pressures and competitive dynamics. While the community remains polarized by the stock's recent price action, many long-term shareholders are actively accumulating shares on dips, betting that the companys distribution strength and international expansion will trigger a major reversal ahead of upcoming earnings.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global Inc. is experiencing heightened volatility and trading volume as investors react to renewed geopolitical tensions in the Strait of Hormuz, which threaten to disrupt critical global LNG supply routes. The community is actively debating the company's long-term valuation and capacity for record EBITDA growth against the backdrop of potential Middle East supply constraints and recent financing developments.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is trending due to anticipation surrounding the FCC's potential approval of a Notice of Proposed Rulemaking (NPRM) for the company's 900 MHz spectrum band. The community is focused on recent capital strengthening and active spectrum rebanding efforts as key catalysts, while monitoring legislative developments and FCC meeting agendas for validation of the long-term thesis.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is seeing increased investor focus due to anticipation surrounding the FLAMINGO-01 Phase III clinical trial, with the community closely tracking potential catalysts like regulatory updates and upcoming data presentations. Discussion is centered on the company's efforts to expand trial eligibility and the broader strategic implications of its peptide vaccine platform within the oncology sector.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is facing a period of heightened market scrutiny as investors weigh solid quarterly performance and recurring revenue growth against concerns regarding slowing US procedure growth and intensifying competitive pressures in international markets. The community remains divided, with long-term bulls highlighting the company's strong operational moat and robotic surgery dominance, while more cautious participants are focused on the stock's recent volatility and whether its premium valuation remains justified amidst moderating expansion.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors digest news of its strategic partnership with the U.S. Army to develop domestic rare earth processing, alongside its official inclusion in the Russell 3000 index. While the community is split between bullish sentiment regarding the company's long-term role in U.S. supply chain independence and bearish accusations of it being a highly volatile, diluted, or fraudulent play, active discussion is dominated by debates over its massive short interest, potential for a squeeze, and its aggressive expansion into military and government-backed projects.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is facing significant selling pressure and heightened volatility as the market digests the recent TopBuild acquisition, with investors split between frustration over share dilution and confidence in Brad Jacobs' long-term consolidation strategy. While the community remains divided over the immediate price action and the impact of institutional selling, many are using the dip to accumulate shares, viewing the current weakness as a temporary mechanical hurdle in a multi-year growth story.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Investors are actively debating market volatility and the impact of geopolitical tensions, particularly as the community analyzes the potential for a tech sector correction despite recent stabilization attempts. Trading activity remains dominated by intense discussions around monthly option expiration dynamics, with many monitoring critical support levels and the sustainability of AI-driven capital expenditure.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing extreme volatility driven by a combination of retail-driven sentiment, massive options expiration activity, and algorithmic trading. The community remains deeply divided, with some investors viewing the price action as blatant market manipulation while others are actively buying the dip, banking on a long-term recovery rooted in AI infrastructure demand.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to heightened investor focus on the upcoming FDA advisory committee meeting and an ongoing patent lawsuit that has introduced significant volatility and legal uncertainty. Despite this, the community remains actively engaged in discussions regarding the strength of HOPE-3 trial data, the company's recent expansion of its San Diego manufacturing footprint, and expectations for a favorable regulatory path for its lead candidate, deramiocel.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal...

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

The Biology Came First.

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor Reports First Quarter 2026 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the...

Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026

Xencor (NASDAQ:XNCR) used a webcast during Digestive Disease Week 2026 to highlight Phase I results for its TL1A-targeting monoclonal antibody XmAb942 and to outline preclinical data supporting...

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the...

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Projected to Post Earnings on Wednesday

Xencor (NASDAQ:XNCR) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-xencor-inc-stock...

Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assig...

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

Xencor Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$17.47
Prev Close	$14.95
Open	$14.68
Dividend Yield	0.00%
50-Day Moving Average	$13.10
Beta	1.42
Avg. Volume	947,426.36
PE Ratio	-6.50

52-Week High	$18.69
52-Week Low	$6.92
Market Capitalization	$1.11B
EPS (Annual)	-$1.24
Price to Book	2.15
Revenue Per Employee	$482,984.61

Feed

News

Sentiment

Earnings

Fundamentals

Info

XNCRXencor Inc

Latest XNCR News